The University of Oxford suggested that the end of 2020 is possible for the availability of a Covid-19 vaccine candidate being developed with AstraZeneca, but expressed caution about the timeline.
An experimental coronavirus vaccine being developed by AstraZeneca and the University of Oxford was safe and produced an immune response in early-stage clinical trials, data showed, keeping alive the hope AZD1222 could be in use by the end of 2020.
Phase I data from the Covid-19 vaccine under development by AstraZeneca and Oxford University’s Jenner Institute is showing a robust defense against the novel coronavirus that has infected more than 13 million people across the globe.
Developing an ‘Inverse Vaccine’ for Type 1 Diabetes Published: July 14, 2020 By Chelsea Weidman Burke BioSpace What do you get when you mix certain immune cells with vitamin D and a disease-provoking molecule? An innovative new vaccine for type 1 diabetes. “We are trying to educate the immune system to teach it what […]
Recently published scientific studies include research into whether Covid-19 immunity might not be possible.
An article raising concern about the safety of using hydroxychloroquine as a treatment of COVID-19 that forced the World Health Organization to temporarily suspend a clinical study involving the drug was retracted.
Scientists resumed COVID-19 trials of the now world-famous drug hydroxychloroquine, as confusion continues to reign about the anti-malarial hailed by U.S. President Donald Trump as a potential “game-changer” in fighting the pandemic.
British medical journal The Lancet has concerns about data behind an influential article that found hydroxychloroquine increased the risk of death in COVID-19 patients, a conclusion that undercut scientific interest in the medicine championed by U.S. President Donald Trump.
Sanofi temporarily stopped recruiting new COVID-19 patients for two clinical trials on hydroxychloroquine and will no longer supply the anti-malaria drug to treat COVID-19 until concerns about safety are cleared up.
France, Italy and Belgium acted to halt the use of hydroxychloroquine to treat patients suffering from COVID-19 amid questions about the safety of the generic anti-malaria drug.